A5040193086- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Esophageal and GI Pathology
- Neuroendocrine Tumor Research Advances
- Advanced Radiotherapy Techniques
- Myasthenia Gravis and Thymoma
- Head and Neck Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Pituitary Gland Disorders and Treatments
- Brain Metastases and Treatment
- Peptidase Inhibition and Analysis
- Meningioma and schwannoma management
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging Techniques and Applications
- Effects of Radiation Exposure
- Metastasis and carcinoma case studies
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Breast Cancer Treatment Studies
- Sarcoma Diagnosis and Treatment
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2024
Shanxi Medical University
2023
Chinese University of Hong Kong
2023
University of Molise
2023
University of Rome Tor Vergata
2023
Hebei Medical University
2023
Fourth Hospital of Hebei Medical University
2023
Aristotle University of Thessaloniki
2023
Peking Union Medical College Hospital
2010-2022
Weatherford College
2022
<h3>Importance</h3> The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non–small cell lung cancer (NSCLC). <h3>Objective</h3> To evaluate the effect PORT using modern techniques on survival and safety patients with NSCLC after complete resection adjuvant chemotherapy. <h3>Design, Setting, Participants</h3> PORT-C randomized clinical trial was conducted 394 treated 4 cycles platinum-based chemotherapy between January 2009 December 2017. Data were...
BACKGROUND: The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive-stage small cell lung cancer (ED-SCLC). METHODS: Between January 2003 and December 2006, records 119 who were diagnosed ED-SCLC (all distant metastasis [M1]) included in study. Sixty received chemotherapy (ChT) TRT (ChT/TRT), 59 ChT alone. regimens consisted either carboplatin etoposide (CE) or cisplatin (PE). total dose ranged from 40 60 grays (Gy)...
For patients with resected pathological stage IIIA-N2 non-small cell lung cancer (NSCLC), the role of postoperative radiotherapy (PORT) is not well defined. In this single-institutional study, we re-evaluated effect PORT on overall survival (OS) as tumor control in subgroup patients.In 2003-2005, 221 consecutive NSCLC at our institution were retrospectively analyzed an institutional review board-approved study. The OS, cancer-specific (CSS), and disease-free (DFS) was evaluated using...
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for locally advanced non-small-cell lung cancer (LA-NSCLC), whereas responses to anti-programmed cell death-1 (PD-1) or death-ligand 1 (PD-L1) are heterogeneous. Though consolidation ICI following concurrent chemoradiotherapy (cCRT) improves survival of NSCLC, this regimen is challenging patients with bulky tumors due excessive target volumes and radiation-resistant hypoxia during upfront cCRT, leading...
Double-agent intravenous chemotherapy concurrent with radiotherapy is the standard of care for patients inoperable esophageal cancer. However, tend to tolerate less well age and comorbidities. It essential find a better treatment modality that improves survival outcomes without reducing quality life.To evaluate effectiveness simultaneous integrated boost (SIB-RT) consolidated oral S-1 aged 70 years older squamous cell carcinoma (ESCC).This multicenter, phase III randomized clinical trial was...
Esophageal squamous cell carcinoma (ESCC) patients with regional lymph node metastases have poor prognosis after surgery. The purpose of this study was to investigate the impact various treatment modalities on survival in these patients.We retrospectively reviewed data from 349 who had undergone left transthoracic esophagectomy for thoracic ESCC January 2008 December 2010 at our institute. All lesions mid or lower third segment and pathological positive metastasis. Of patients, 143 received...
Information on the optimal salvage regimen for recurrent esophageal cancer is scarce. We aimed to assess patterns of locoregional failure, and evaluate therapeutic efficacy therapy along with prognostic factors in thoracic squamous cell carcinoma (TESCC) after radical esophagectomy.A total 193 TESCC patients who were diagnosed recurrence surgery received treatment at our hospital retrospectively reviewed from 2004 2014. The first failure assessed. post-recurrence survival rate was determined...
Abstract Background The role of postoperative radiotherapy in pathological T2–3N0M0 esophageal squamous cell carcinoma is unknown. We aimed to evaluate the efficacy and safety patients with thoracic carcinoma. Materials Methods Patients aged 18–72 years stage after radical surgery without neoadjuvant therapy were eligible. randomly assigned alone or receive 50.4 Gy supraclavicular field 56 mediastinal 28 fractions over 6 weeks. primary endpoint was disease-free survival. secondary endpoints...
Retrospective studies have shown that adjuvant treatment improves survival of patients with stage IIB-III esophageal squamous cell carcinoma, but there is no evidence from prospective trials so far.Patients pathological carcinoma were randomly assigned to receive surgery alone (SA), postoperative radiotherapy (PORT), or concurrent chemoradiotherapy (POCRT). PORT received 54 Gy in 27 fractions; the POCRT group 50.4 28 fractions, plus chemotherapy paclitaxel (135-150 mg/m2 ) and cisplatin...
Thoracic spinal meningiomas (TSMs) are common intradural extramedullary tumors and usually surgically treated. Although surgery generally results in positive outcomes, some patients experience residual or new neurological impairments. The authors conducted a multicenter cohort study to investigate prognostic factors that affect functional recovery following TSM resection. A retrospective from 3 tertiary centers was included all who underwent resection between 2015 2023. Patients had minimum...
The role of adjuvant radiotherapy (RT) for patients with stage III thymoma after complete resection is not definite. Some authors have advocated postoperative RT tumor resection, but some others suggested observation. In this study, we retrospectively evaluated the effect on survival as well control in Masaoka thymoma.Between June 1982 and December 2010, 65 who underwent entered study. Fifty-three had surgery (S + R) 12 only alone). Of RT, 28 three-dimensional conformal (3D-CRT)/intensity...
Abstract Background. Consistent results are lacking as regards the comparative effectiveness of intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal (3DCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). Patients and Methods. treated definitive (RT) between 2002 2010 were retrospectively reviewed. Overall survival (OS), local-regional progression-free (LRPFS), distant metastasis-free (DMFS), (PFS) compared among irradiated different techniques....
<b><i>Background:</i></b> The aim of this study was to retrospectively analyze the effect postoperative intensity-modulated radiotherapy (IMRT) on recurrence and survival in lymph node-positive or stage III thoracic esophageal squamous cell carcinoma (TESCC) patients, evaluate its role TESCC therapy. <b><i>Methods:</i></b> We enrolled 538 patients who underwent radical resection with (S + R) without (S) IMRT. median total IMRT dose 60 Gy....
To investigate the safety and tolerability of simultaneous integrated boost (SIB) technique concurrent with elective nodal irradiation (ENI) dual-drug chemotherapy for patients unresectable esophageal cancer. In phase I, prophylactic PTV received a stable dose 50.40Gy/1.80Gy/28f while area was planned 3 consecutive levels: first level 60.76Gy/2.17Gy/28f, then escalated approximately every 2 Gy. ENI incorporated in Clinical Target Volume (CTV), paclitaxel nedaplatin were given concurrently at...
Abstract Background Concurrent epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) with radiotherapy in patients EGFR ‐mutant unresectable stage III non‐small cell lung cancer (NSCLC) might improve survival. However, both treatments carry a potential risk of pneumonitis. Methods Between May 2012 and December 2017, NSCLC treated concurrent EGFR‐TKI were enrolled this retrospective study. The baseline characteristics evaluated to determine correlations toxicity development....
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin as regimen conversional chemoradiotherapy (cCRT) in locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma (ESCC).
To establish a prediction model in selecting fit patients with resected pIIIA-N2 non-small cell lung cancer (NSCLC) for postoperative radiotherapy (PORT), and evaluate the clinical practice.Between January 2003 December 2005, 221 NSCLC were retrospectively analyzed. The effect of PORT on overall survival (OS) different clinicopathological factors was evaluated results used to select PORT.Compared control, significantly improved OS smoking index ≤400 (P = 0.033), cN2 0.003), pT3 0.014),...